Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
Clive Ballard, David Kreitzman, Stuart Isaacson, I-Yuan Liu, James C. Norton, George Demos, Hubert H. Fernandez, Tihomir Ilić, Jean‐Philippe Azulay, Joaquim J. Ferreira, Victor Abler, Srdjan Stankovic
Topics & Concepts
TolerabilityDiscontinuationMedicineClinical Global ImpressionAdverse effectInternal medicinePlaceboPsychosisPsychiatryPathologyAlternative medicineParkinson's Disease Mechanisms and TreatmentsPharmacology and Obesity TreatmentSchizophrenia research and treatment